Clinical Trial Update: Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab with radiosurgery for brain metastases from non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Brain Metastases from Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN